Education
About Us
Working with TipRanks
Follow Us
Pfizer Inc (DE:PFE)
:PFE
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.5Last Year’s EPS
0.53Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 4.89%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
Pfizer's earnings call highlighted a strong R&D pipeline and strategic focus on growth areas such as oncology and cardiometabolic segments, alongside significant growth in key products. However, the company also faced challenges, including a decline in overall revenue and potential impacts from global trade uncertainties and competition. Despite these challenges, Pfizer demonstrated strong operational efficiency and cost management, positioning itself for future growth.Company Guidance
During Pfizer Inc.'s First Quarter 2025 Earnings Conference Call, the company reaffirmed its guidance for the fiscal year 2025, projecting total company revenues to be in the range of $61 to $64 billion and adjusted diluted earnings per share between $2.80 and $3.00. The call highlighted Pfizer's focus on improving R&D productivity, with anticipated milestones including at least four regulatory decisions and up to nine phase three readouts. The company reported first-quarter revenues of $13.7 billion, a 6% operational decline, primarily due to lower PAXLOVID revenues and changes in the IRA Medicare Part D redesign. However, Pfizer recorded strong growth in several key products, with adjusted diluted earnings per share reaching $0.92, attributed to robust gross margin and cost management. The company also emphasized its strategic priorities of enhancing shareholder value, maintaining a strong dividend policy, and pursuing disciplined capital allocation with reinvestments in R&D and potential external opportunities, despite the macroeconomic uncertainties such as potential tariffs and the complex global trade environment.Strong R&D Pipeline and Strategic Focus
Pfizer emphasized strengthening its R&D organization with a focus on cardiometabolic and oncology segments. Anticipated multiple key milestones include at least four regulatory decisions and up to nine phase three readouts in 2025.
Significant Revenue Growth in Key Products
The Vintechl family of products saw robust growth, and the oncology portfolio, specifically Tatsit, grew by 25% in revenue. The company also reported a 40% revenue growth for Northrop America.
Operational Efficiency and Cost Management
Pfizer reported a 12% operational decline in total adjusted operating expenses and is on track to deliver $4.5 billion in cumulative net cost savings by the end of 2025.
Strong Performance in US and International Markets
Pfizer reported strong contributions across its product portfolio and noted significant market growth in international regions, particularly with products like Nortech, Tatsit, and Blurbbrand.
---
DE:PFE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:PFE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | €20.25 | €20.98 | +3.58% |
| Feb 04, 2025 | €25.59 | €24.86 | -2.89% |
| Oct 29, 2024 | €25.86 | €25.48 | -1.46% |
| Jul 30, 2024 | €27.49 | €27.38 | -0.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pfizer Inc (DE:PFE) report earnings?
Pfizer Inc (DE:PFE) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Pfizer Inc (DE:PFE) earnings time?
Pfizer Inc (DE:PFE) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pfizer Inc stock?
The P/E ratio of Pfizer is N/A.
What is DE:PFE EPS forecast?
DE:PFE EPS forecast for the fiscal quarter 2025 (Q2) is 0.5.
---
